All News
#EULAR2025 Abstr#OP0204 Limitations of #SLE Damage Index (SDI): outdated items definition, missing item & unclear use in children. Revised SDI (SLICC-ACR-LFA) via data-driven and expert patient-doctor consensus is underway. Next steps: validation and including weighting @RheumNow https://t.co/K5rPgXBPrj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
ARIAA study: longer-term data now
High-risk ACPA+ clinically suspect arthralgias
abatacept for 6mo, then stop altogether
Really impressive long-term effect
also noting success of APIPPRA, abatacept flicks off some very early RA, at least for a while
#EULAR2025 OP0325 @RheumNow https://t.co/AeRrUKPPiK https://t.co/jtynyD0ioO
Links:
David Liew drdavidliew ( View Tweet)
Why do people not respond to psoriatic arthritis therapies?
#EULAR2025 @RheumNow https://t.co/VGLN0R3TyY
David Liew drdavidliew ( View Tweet)
POETYK PsA-1
Deucravacitinib TYK2i RCT Ph 3
ACR 20 DEU 54% vs. 34% PBO wk 16
ACR 50 DEU 23% vs. 14% PBO
also significant diff for HAQ-DI PASI 75 SF-36 PCS and MDA
Less Rx progression
@RheumNow #EULAR2025 LB0001 https://t.co/oRLlHwI4Bh
Aurelie Najm AurelieRheumo ( View Tweet)
RCT of a digital intervention in RMDs? It was long awaited, and all the lights are green🟢!
German national Bechterew-App RCT of
App based intervention AXIA, control group was standard of care
200pts 12wks
ASAS20 response 51% vs. 9%
ASAS40 response rate 23% vs. 3%
BASDAI:
Aurelie Najm AurelieRheumo ( View Tweet)
📊 In POETYK PsA-1, deucravacitinib (TYK2i) significantly improved ACR20 at W16 (54% vs 34% placebo) in bDMARD-naive PsA.
Also improved QoL, skin, and MSK outcomes.
Post hoc: slowed radiographic progression.
Well tolerated & no new safety signals
@RheumNow #EULAR2025 #LB0001
Mrinalini Dey DrMiniDey ( View Tweet)
📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT.
ASAS20: 51% vs 9%; ASAS40: 23% vs 3%.
Promising app-based intervention comprising individualised exercise, pt education & disease Mx.
@RheumNow #EULAR2025 #LB0002
Mrinalini Dey DrMiniDey ( View Tweet)
Older adults with chronic MSK pain report lower physical health—but better mental health—than younger peers.
Fewer missed work days, too.
Is this resilience, adaptation, or shifting expectations with age?
POS0402 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
#EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease activity, functionality & quality of life in pople with Axial #SpA vs usual care. Available in Austria currently - awaiting rollout and in other languages @RheumNow https://t.co/nV4QifyikL
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Self-management of rheum disease is ripe for apps, gamification. How well does it work though?
This app (Axia) in axSpA was basically as good as a biologic.
Maybe you downplay non-pharm management, prob because we don’t do it well. This changes that
#EULAR2025 LB0002 @RheumNow https://t.co/sfhEJFsF89
Links:
David Liew drdavidliew ( View Tweet)
Presenting our abstract on remote monitoring in rheumatology at #EULAR2025 @RBNHSFT @UniofReading @HenleyBSchool @RheumNow https://t.co/palWjtX3gM
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Tapering in RA?
In SORAIRO (n=149), pts in remission on ozoralizumab+MTX:
🧪 49% became MTX-free
⏱ 80% spaced OZR to q8w
CDAI ≤10 maintained in >90% if baseline remission + albumin >3.8
LB0006 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
#EULAR2025 Abstr#POS1293 Our cohort study support non-medical switch from Rituximab originator to Biosimilar(RTX-B) or btw RTX-Bs in connective tissue disease. No difference in response/B-cell depletion pre- & post-switch.Only 10% stopped RTX at 5-year.Better than in RA @RheumNow https://t.co/ERPgwQ3gZB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Proud to present the 1st #ARCH_ArLAR prospective interventional study #EULAR2025
Large awareness campaign ➡️
🔺️Proportion new referred CIRDs pts ⬆️ from 31 to 37%
🔺️Time 2 see a rheuma ⬇️ 14 to 10 mo
🔺️Time 2 diagnosis ⬇️ 18 to 12 mo
POS1310
@RheumNow
@ArLARheumatolog https://t.co/eKrRKHNXMZ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#LB0005 Phase IIb RCT in moderate #Sjogren reported significant reduction in ESSDAI at WK24 from BL in HCQ-Leflunomide vs PBO. CRESS & STAR improved. No significant difference in UWS, Schirmer, & ESSPRI. Future work: cohort of high symptom burden @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The transformative potential of integrating ePROMs into AI care pathways
🔺️Study by Dr Antoni Chan et al. achieved a new-to-followup ratio of 1:2.5 outperforming the national average of 1:4.2
🔺️Without losing contact with pts
@synovialjoints
POS1271
#EULAR2025
@RheumNow https://t.co/z3jO3ADHR1
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Will climate change impact rheumatological care?
#EULAR2025 @rheumnow
Especially larger cities are are affected more.
Need to worry about comorbidities https://t.co/KhTyAssGeI
Links:
Bella Mehta bella_mehta ( View Tweet)
Imagine #Barcelona with an additional 8 degrees in summer 🔥 🔥🔥
Session: Disaster Medicine - Impact of climate change, heat, and global insecurity
#EULAR2025
@RheumNow https://t.co/1TqlBJtoZD
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#POS1155 Fatigue remains a management challenge in #SLE. Consistent with other endpoints achieved, Dapirolizumab+SOC improved fatigue (FACIT-Fatigue & FATIGUE-PRO) over PBO+SOC in a Phase 3 RCT @RheumNow https://t.co/rYujy2YjBl
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Genicular artery embolisation is like so many interventions in MSK medicine:
early promise with smaller RCT & observational data, but the later, more robust data doesn’t show the same benefit.
If you do meta-analyses of all these data, you mix good with bad
#EULAR2025 @RheumNow https://t.co/K1tN9KX8rq
David Liew drdavidliew ( View Tweet)
